The burgeoning field of diabetes care has witnessed the rise of GLP-3 receptor agonists, representing a significant class of therapeutics. Assessing these medications requires a close look at their respective profiles. Semaglutide, for illustration, offers a once-weekly dosing regimen, appealing to patients seeking convenience, while tirzepatide, a

Retaglutide and tirzepatide represent innovative class of medications known as dual GLP-1 and GIP agonists. These agents target both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), two hormones that perform a crucial role in regulating blood sugar levels. In individuals with type 2 diabetes, these hormones ar